High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII.
about
Designed ankyrin repeat proteins: a new approach to mimic complex antigens for diagnostic purposes?Prophylactic dosing of factor VIII and factor IX from a clinical pharmacokinetic perspective.Comparison of clot-based, chromogenic and fluorescence assays for measurement of factor VIII inhibitors in the US Hemophilia Inhibitor Research Study.Inhibitors in congenital coagulation disorders.Haemophilia A: from mutation analysis to new therapies.Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.Quantitation of anti-factor VIII antibodies in human plasma.Long-term exposure to Myozyme results in a decrease of anti-drug antibodies in late-onset Pompe disease patients.Acquired hemophilia A: a frequently overlooked autoimmune hemorrhagic disorder.Factor VIII inhibitors in hemophilia A: rationale and latest evidenceAntibody formation and specificity in Bethesda-negative brother pairs with haemophilia A.Product-dependent anti-factor VIII antibodies.Long-term anti-FVIII antibody response in Bethesda-negative haemophilia A patients receiving continuous replacement therapy.Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs.Inhibitor development, immune tolerance and prophylaxis in haemophilia A--the need for an evidence-based approach.A flow cytometry evaluation of anti-FVIII antibodies: correlation with ELISA and Bethesda assay.ELISA system for detection of immune responses to FVIII: a study of 246 samples and correlation with the Bethesda assay.IgG subclasses of FVIII inhibitors in an argentine cohort of severe hemophilia A patients: Analysis by flow cytometry.Limit of detection and threshold for positivity of the Centers for Disease Control and Prevention assay for factor VIII inhibitors.Low detection rate of antibodies to non-functional epitopes on factor VIII in patients with hemophilia A and negative for inhibitors by Bethesda assay.Severe haemophilia A patients have reduced numbers of peripheral memory B cells.Detection of all anti-factor VIII antibodies in haemophilia A patients by the Bethesda assay and a more sensitive immunoprecipitation assay.Comparative immunogenicity of recombinant B domain-deleted porcine factor VIII and Hyate:C in hemophilia A mice presensitized to human factor VIII.Recombinant factor VIII Fc fusion protein for the prevention and treatment of bleeding in children with severe hemophilia A.The IgG autoimmune response in postpartum acquired hemophilia A targets mainly the A1a1 domain of FVIII.Characterization of inhibitors to FVIII with an ELISA in congenital and acquired haemophilia A.Anti-C1 domain antibodies that accelerate factor VIII clearance contribute to antibody pathogenicity in a murine hemophilia A model
P2860
Q34692067-B033E860-FDF5-4426-BE72-D4C833A67B90Q35112459-C9A6EF33-0AF1-4625-9803-04531EE97F4FQ35771007-9FA0970D-3A35-4E97-9A73-0CBC0D2E5409Q35937076-6AF877C9-41F8-42A1-9330-B33D5C7DEA0CQ36148386-CC7C25CB-7A48-4431-946B-22F4347A6F60Q36707550-112C9831-F9AE-418E-9E13-24094789E5D2Q37129689-C27B800E-C539-4ED7-8A7C-BB454F5A673CQ37394520-4028DB4A-72A0-44BF-B0D9-E26D6264B88BQ37704765-36BCD2FA-499E-4400-A702-7DFB8592CF35Q38101041-F1B9CB73-F354-4D78-892A-47968B47FB3AQ39591702-7773B78B-90AB-410E-8685-5EFE468769D0Q42913024-F84643B6-3096-4D04-8F35-D5132259717CQ43579343-53A905DE-A9CA-4E7F-8279-DD3FC5147833Q45858508-ED86A586-73BC-452E-BBF8-2479D10D2844Q45859666-DB33240E-D986-42F8-A4C1-4A16F311E153Q45864882-00F1930C-0384-48FD-9E50-5433396689AFQ45868089-F9B1386C-7960-478A-8730-41ED7DCDCBC0Q45868834-D2612B33-5E4C-49E4-ADC6-2B9A06E92449Q45870641-EE739A1C-C1A4-4A6E-891A-0E0C35806FA7Q45870951-4C14E05C-4D8A-4D8C-BA48-D380C8225806Q45873173-12A51A00-6FC5-4A0B-9237-4D8B6CEDCBE2Q45873668-FAF73BB7-4F33-4B3A-A229-94C34D9DFE69Q45874820-70D972FB-6577-452F-8AB7-82BCDFDFEE90Q45875309-0BD7DB72-2E53-4B0B-B6FA-661B60BB6063Q45880409-D369ACFA-3536-488D-9E07-384C1D73017DQ45888811-40DC0A2D-CC6D-4225-9107-AC45DEB072C2Q57448320-AF2AC430-06A5-4237-8566-010998B01A11
P2860
High incidence of anti-FVIII antibodies against non-coagulant epitopes in haemophilia A patients: a possible role for the half-life of transfused FVIII.
description
1996 nî lūn-bûn
@nan
1996年の論文
@ja
1996年学术文章
@wuu
1996年学术文章
@zh
1996年学术文章
@zh-cn
1996年学术文章
@zh-hans
1996年学术文章
@zh-my
1996年学术文章
@zh-sg
1996年學術文章
@yue
1996年學術文章
@zh-hant
name
High incidence of anti-FVIII a ...... half-life of transfused FVIII.
@en
High incidence of anti-FVIII a ...... half-life of transfused FVIII.
@nl
type
label
High incidence of anti-FVIII a ...... half-life of transfused FVIII.
@en
High incidence of anti-FVIII a ...... half-life of transfused FVIII.
@nl
prefLabel
High incidence of anti-FVIII a ...... half-life of transfused FVIII.
@en
High incidence of anti-FVIII a ...... half-life of transfused FVIII.
@nl
P2093
P921
P1476
High incidence of anti-FVIII a ...... half-life of transfused FVIII
@en
P2093
P304
P356
10.1046/J.1365-2141.1996.D01-1705.X
P407
P577
1996-06-01T00:00:00Z